市場調査報告書：医薬品の消費者：米国

Abstract

In spite of the enormous successes in the market for life-enhancing prescription medication, the industry is plagued by a wide variety of issues that prevent increased sales, ranging from mistrust of pharmaceutical companies, increasing reluctance on the part of physicians to meet with drug company representatives, lack of awareness regarding some illnesses, fear of side effects, concerns regarding effectiveness of products, lack of access to healthcare, as well as fears that pharmaceutical products may be addictive. This Mintel report focuses on methodologies for combating all of these issues via examination of consumer attitudes toward the use of pharmaceuticals in combating the following illnesses:

Depression
General anxiety
Social anxiety
ADHD
Sexual dysfunction
Insomnia
Allergies
Obesity

The report is divided in two sections, with the first dealing with market-wide issues relevant to the sales of pharmaceuticals, including distrust of pharmaceutical companies, access to medical insurance that covers pharmaceuticals, competition from OTC, generic, and alternative medication, attentiveness to D2C advertising, and the consumer' s research process. The second half of the report focuses on the prevalence, treatment, and potential sales growth for prescription medication by specific conditions.

Scope and Themes
What you need to know
Definition
Data for this report
Abbreviations and terms
Abbreviations
Terms
Executive Summary, Part I: Market Wide Issues
Access to healthcare the primary obstacle to increased sales
Consumers losing faith in pharmaceutical companies
OTC and Rx medication increasingly competitive
Attentiveness to advertising dependent on prevalence of condition
Younger respondents more attentive, but less able to receive prescriptions
Consumers more active in researching conditions and treatments
Selling the branded product when generics are available
Healthcare Coverage
Introduction
Access to healthcare coverage
- Figure 1: Access to health insurance, November 2007, and May 2006-June 2007
- Figure 2: Rx prevalence of usage, by type of medical insurance, November 2007
Distrust of Pharmaceutical Companies
Consumer distrust of pharmaceutical companies
- Figure 3: Attitudes toward prescription medicine, by availability of medical insurance, November 2007
Trust for pharmaceutical ads by age
- Figure 4: Attitudes regarding trust and pharmaceutical companies, by age, November 2007
Doctors reject pharmaceutical sales tactics
Consumer attitudes toward their doctors
- Figure 5: Attitudes towards doctors' roles in choosing pharmaceuticals, June 2002-May 2003, and May 2006 to June 2007
Fear of side effects
- Figure 6: Attitudes regarding side effects of drugs, by gender, May 2006 to June 2007
Attitudes to media presentation of side effects
- Figure 7: Attitudes regarding the presentation of side effects in D2C advertising, by age, November 2007
Competition from OTC medication
Preferences between OTC and Rx medication
- Figure 8: Attitudes toward OTC medicine, by age, May 2006 to June 2007
- Figure 9: Choice of OTC medicine over prescription, by age, November 2007
Comparison of Rx usage across illnesses in the Internet population
- Figure 10: Use of prescription medication, by condition, November 2007
Competition from/Attitudes to Alternative Medicine
- Figure 11: Attitudes toward alternative medicine, June 2002-May 2003, May 2004-May 2005, May 2006 to June 2007
- Figure 12: Attitudes toward alternative medicine, by age, November 2007
Attentiveness to Advertising
Introduction
- Figure 13: Paying attention to D2C advertising, by type of medication, November 2007
- Figure 14: Attentiveness to pharmaceutical ads, by gender, November 2007
- Figure 15: Attentiveness to pharmaceutical ads, by age, November 2007
- Figure 16: Attentiveness to pharmaceutical ads, by race/ethnicity, November 2007
- Figure 17: Attentiveness to pharmaceutical ads, by student status, November 2007
Why ads are watched
- Figure 18: Reasons for watching drug ads, November 2007
- Figure 19: Reasons for watching drug ads, by age, November 2007
The Consumer' s Research Process
General health research
- Figure 20: Ways of reseaching health information, by gender, May 2006 to June 2007
- Figure 21: Ways of researching health information, 2003 vs. 2007
- Figure 22: Ways of researching health information, by age, May 2006-June 2007
Researching healthcare treatments
- Figure 23: Researching pharmaceuticals and treatments, 2003 vs. 2007
- Figure 24: Researching pharmaceuticals and treatments, by gender, May 2006 to June 2007
Buying Generic vs. Brand Name
- Figure 25: Attitudes to brand-name drugs, May 2006 to June 2007
- Figure 26: Attitudes towards name brand and generic drugs, November 2007
- Figure 27: Attitudes towards name brand and generic drugs, by race/ethnicity, November 2007
Executive Summary, Part II: Prevalence of Treatment of Specific Conditions
Use of Rx medication varies based on effectiveness of OTC treatment
Substantial opportunity exists in overweight/obesity and herpes
Potential for viral marketing apparent
Depression category leads in sales, sleep aids in ad spend
Sexual dysfunction is not gender-specific
Some suffering from allergies not aware that they have them
Psychiatric medications continue to face obstacles
A large body of sufferers is not being treated in every condition
Making men comfortable talking about depression
Where does trouble concentrating end and ADHD begin?
Bulleted check list for websites
Prevalence of Conditions and Use of Rx Treatments
Introduction
- Figure 28: Prevalence of ailments trended and percentage with ailments using prescription medication, 2003-07
Substantial opportunity in drugs to combat obesity
Prescription drug use for allergies declining
Emphasis on responsibility should grow herpes market
Depression: Penetration says more about the competition than about the drug
Internet population
- Figure 29: Ailments, have, have had, or friend or family has, November 2007, and May 2006 to june 2007
Comparison of Rx usage across conditions
- Figure 30: Use of prescription medication by condition, November 2007 (GF) and May 2006-June 2007 (NCS)
Prevalence of conditions suffered in Internet population by demographics
- Figure 31: Conditions suffered (self-reported), by age, November 2007
- Figure 32: Conditions suffered (self-reported), by gender, November 2007
- Figure 33: Conditions suffered (self-reported), by household income, November 2007
- Figure 34: Conditions suffered (self-reported), by race/Hispanic origin, November 2007
Sales and Advertising Spend
Sales
- Figure 35: Sales of 20 leading pharmaceutical products for six conditions, 2004 and 2006
Depression medication sales
ADHD medication
Allergy medications
Sleep medications
- Figure 36: Ad spend on sleep medication, 2005 and 2006
Sexual Dysfunction
Introduction
- Figure 37: Suffer or have suffered from sexual dysfunction, by demographic, November 2007
Treatment of sexual dysfunction
- Figure 38: Sexual dysfunction treatment used, by household income, November 2007
Sexual dysfunction medications
Viagra
- Figure 39: Pfizer Viagra Advertisement
Levitra
- Figure 40: Bayer Levitra Advertisement
Cialis
- Figure 41: Lilly Cialis Advertisement
Pollen Allergies
Introduction
- Figure 42: Suffered from nasal allergies/hay fever in last 12 months, by demographic, May 2006 to June 2007
Treatment of allergies
- Figure 43: Nasal allergy treatment used, by age, November 2007
- Figure 44: Allergy treatment used, by race/Hispanic origin, November 2007
Notes on OTC treatment
Allergy shots
Nasal airway surgeries
Allergy medications
Nasonex
- Figure 45: Schering-Plough Nasonex Advertisement
Allegra
Clarinex
Flonase
Overweight and Obesity
Introduction
- Figure 46: Prevalence of being 30 pounds overweight in the last 12 months, by key demographics, May 2006 to June 2007
Xenical
Competition from gastric bypass surgery
Attitudes Towards Sleep Aids and Psychiatric Drugs
- Figure 47: Attitudes towards psychiatric illnesses and drugs and sleep aids, November 2007
Depression
Introduction
Prevalence and treatment with Rx medication by demographic
- Figure 48: Incidence of depression, and Rx treatment, by demographic, November 2007, and May 2006-June 2007
Rx vs. other methods of treatment
- Figure 49: Depression treatment used, by age, November 2007
- Figure 50: Depression treatment used, by race/ethnicity, November 2007
Switching depression medication
- Figure 51: Reasons to change depression medication, by age, November 2007
Depression medications
Effexor
- Figure 52: Effexor advertisement
Zoloft
Wellbutrin
Cymbalta
- Figure 53: Eli Lilly Cymbalta Advertisement
Anxiety
Introduction
- Figure 54: Suffer or have suffered from general or social anxiety, by demographic, November 2007, and May 2006-June 2007
Treatment of general anxiety
- Figure 55: General anxiety treatment used, by age, November 2007
Treatment of social anxiety
- Figure 56: Social anxiety treatment used, by race/ethnicity, November 2007
Switching anxiety medication
- Figure 57: Reasons to change anxiety medication, November 2007
Adhd
Prevalence
- Figure 58: Suffers or has suffered from ADHD or trouble concentrating, by age, November 2007
Treatment of ADHD
- Figure 59: ADHD treatment used, by age, November 2007
ADHD medications
Concerta
Adderall XR
Strattera
Sleep Disorders
Introduction
- Figure 60: Suffered from sleep disorders in last 12 months, by age and gender, May 2006 to June 2007, and November 2007
Treatment of sleep-related problems
- Figure 61: Sleep-related problem treatment used, by gender, November 2007
- Figure 62: Sleep disorder treatment used, by age, November 2007
Treatments for sleep apnea
Sleep disorder medications
Lunesta
- Figure 63: Sepracor Lunesta Advertisement
Ambien
- Figure 64: Sanofi-Aventis Ambien CR Advertisement
- Figure 65: Sanofi-Aventis Ambien CR Advertisement
Rozerem
Requip
- Figure 66: GlaxoSmithKline Requip Advertisement
Appendix: Trade Associations

米国における医薬品の消費者

The Pharmaceuticals Consumer - US - February 2008

Abstract

Table of Contents